HomeCompareEIGR vs ADC

EIGR vs ADC: Dividend Comparison 2026

EIGR yields 115.94% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EIGR wins by $7.14M in total portfolio value
10 years
EIGR
EIGR
● Live price
115.94%
Share price
$1.73
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.32M
Annual income
$2,715,715.87
Full EIGR calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — EIGR vs ADC

📍 EIGR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGRADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGR + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGR pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGR
Annual income on $10K today (after 15% tax)
$9,855.07/yr
After 10yr DRIP, annual income (after tax)
$2,308,358.49/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, EIGR beats the other by $2,239,680.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGR + ADC for your $10,000?

EIGR: 50%ADC: 50%
100% ADC50/50100% EIGR
Portfolio after 10yr
$3.75M
Annual income
$1,398,256.59/yr
Blended yield
37.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

EIGR
Analyst Ratings
11
Buy
Consensus: Buy
Altman Z
-24.5
Piotroski
4/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGR buys
0
ADC buys
0
No recent congressional trades found for EIGR or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGRADC
Forward yield115.94%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$7.32M$178.9K
Annual income after 10y$2,715,715.87$80,797.29
Total dividends collected$6.64M$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: EIGR vs ADC ($10,000, DRIP)

YearEIGR PortfolioEIGR Income/yrADC PortfolioADC Income/yrGap
1← crossover$22,294$11,594.20$10,990$580.36+$11.3KEIGR
2$48,012$24,157.34$12,301$860.26+$35.7KEIGR
3$99,994$48,621.05$14,104$1,298.62+$85.9KEIGR
4$201,631$94,637.59$16,691$2,008.16+$184.9KEIGR
5$394,091$178,346.07$20,580$3,205.09+$373.5KEIGR
6$747,454$325,775.96$26,754$5,330.02+$720.7KEIGR
7$1,377,237$577,460.92$37,196$9,345.14+$1.34MEIGR
8$2,468,047$994,404.26$56,244$17,523.09+$2.41MEIGR
9$4,306,232$1,665,421.46$94,286$35,736.21+$4.21MEIGR
10$7,323,384$2,715,715.87$178,949$80,797.29+$7.14MEIGR

EIGR vs ADC: Complete Analysis 2026

EIGRStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Full EIGR Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this EIGR vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGR vs SCHDEIGR vs JEPIEIGR vs OEIGR vs KOEIGR vs MAINEIGR vs NNNEIGR vs EPRTEIGR vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.